(AP) — AbbVie recently announced that U.S. regulators have approved its drug Humira as a treatment for Crohn’s disease in children. IMS Health says Humira is the biggest-selling brand-name drug in the world. It is approved to treat conditions including Crohn’s disease, rheumatoid arthritis, ulcerative colitis and plaque psoriasis.
The Food and Drug Administration cleared Humira as a treatment for moderate to severe Crohn’s disease in children ages six and older when those children haven’t been helped by other treatments, AbbVie said. The North Chicago, Illinois, company said Humira can be administered at home, unlike similar drugs used to treat the condition.
During the second quarter, revenue from Humira jumped 26 percent to $3.29 billion.